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We were also cautious with accepting these lungs because it's a relatively initial stage. Also, for example, when the patient chokes and it's a DCD donor, we have a lower threshold of declining this organ. Another example, one of the predictors is also gastro-oesophageal reflux. Thus, we should be more aggressive with patients with early symptoms in terms of fundoplication. We can also be more cautious with preventing infections after lung transplantation. These are the predictors of BOS.
Dr W. Klepetko (Vienna, Austria): This finding is somewhat surprising, because by theory, you would expect that the absence of brain death should transfer in better initial graft function, less initial trauma, and in the long term transfer to better results with regard to BOS. You showed the opposite. How can you explain?
Dr Sabashnikov: I completely agree with your point, and previous papers with shorter follow-up showed no difference or even better results in terms of BOS-free survival in the beginning in DCD patients. This development can also be seen on my graph, where there is an initial period when DCD group showed better freedom from BOS.
Dr Klepetko: At arrival PO2/FiO2 was better. 24 hours later it turned around.
Dr Sabashnikov: Yes, and for that reason, we can say that there was no brain damage. However, it was a significant ischaemic insult because we have to switch off therapy and we had to wait for five minutes until cardiac arrest.
In the UK, for example, we are not allowed to pretreat potential donors. We are not allowed to give heparin. It might lead to building of several micro-clots despite sufficient retrograde perfusion.
So there are different opinions regarding DCD and DBD donation and different pathophysiological explanations of these results.
Dr Klepetko: One minor question. Is primary pulmonary hypertension not an indication for lung transplantation in Great Britain because you have no case of primary pulmonary hypertension in your series? Dr Sabashnikov: We had around 7% of patients with primary pulmonary hypertension operated. However, after propensity score matching, all of them were excluded. This is because one of the factors which propensity score matching was based on is diagnosis, the recipient diagnosis. And as DCD group had almost no pulmonary hypertension, the propensity score matching excluded this diagnosis from the analysis. In some countries, such as Germany, it remains virtually unknown, but in the UK, in contrast, it provided 41% of deceased organ donors in 2014 [1] . In a number of Western European countriesBelgium, Netherlands, the UK [2]-and in Australia and Canada, but to a much lesser extent in the USA, lung transplant from such donors has come to comprise a significant proportion of all activity.
In general, the results have been excellent. Except for one early, single institution publication [3] , all the reports show a striking similarity in early survival between transplants from (donation after cardiac death) DCD or DBD donors. Examples of virtually superimposed survival curves are to be found in papers from centres as diverse as Melbourne [4] and Groningen [5] . While there must be an element of publication bias (one might not submit inferior results) the similarity of early survival from around the world is striking.
There are many reasons to expect similar results. The donor lung is not subjected to the rigours of brain stem death and may have less inflammatory activation. The lung has been considered the ideal organ to retrieve from DCD donor [6] .
The same is seen in a landmark study from Harefield [7] , but theirs is almost the first to examine the medium and longer period (up to 7 years) after transplant. They are the first to suggest, in any serious way, that these lungs are not as good as the standard, from DBD. The report details a divergence in survival, and in freedom from bronchiolitis obliterans syndrome (BOS), the manifestation of irreversible chronic rejection in the lung.
The report comes from an institution with a very respectable activity in lung transplantations, more than 300, in a 5-year period, and a positive approach to DCD lung donation-they comprised 20% of the total. So the results have to be taken seriously, but at the moment stand alone; the Australian experience had no difference in survival (but did not examine BOS) out to 4 years. In Leuven, both BOS and survival were the same out to 3 years, but the numbers (21 patients) were small enough for a difference not to have been detected [8] .
There are a number of reasons why BOS (the major determinant of medium and late survival) might be more common after DCD donation. In the donor, while lung inflation protects the lung parenchyma from ischaemic damage, its effect on the airway, usually perfused from the systemic circulation, is unknown. The possibility of a link between airway ischaemia and BOS is increasingly recognized [9] .
Another parallel comes from the liver, where ischaemic cholangiopathy is a significant and dreaded complication when retrieval is from a DCD donor-it is almost unknown in DBD livers. There are obvious analogies between the epithelial biliary tree and its equivalent in the lung.
In this series, there was a measurably higher incidence of primary graft dysfunction, which is itself a risk factor for BOS. A possible cause for this might be a longer agonal phase, as suggested in one early series [10]-we do not have that information from the Harefield group.
What is the next step? For the moment, the consensus must remain that these lungs, from DCD donors, are as good as those from DBD donors. But all those in the field must examine their medium term survival, and incidence of BOS, preferably in Registries with sufficient numbers to avoid a type ll statistical error. If a similar difference is found, the risk factors for early BOS must be investigated. Is it related to particular donor factors, such as prolonged agonal phase, or extended warm ischaemia? The lung transplant community cannot afford to turn its back on this huge and invaluable source of donor organs.
